| Title |
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
|
|---|---|
| Published in |
PharmacoEconomics, July 2019
|
| DOI | 10.1007/s40273-019-00825-1 |
| Pubmed ID | |
| Authors |
Seamus Kent, Frauke Becker, Talitha Feenstra, An Tran-Duy, Iryna Schlackow, Michelle Tew, Ping Zhang, Wen Ye, Shi Lizheng, William Herman, Phil McEwan, Wendelin Schramm, Alastair Gray, Jose Leal, Mark Lamotte, Michael Willis, Andrew J Palmer, Philip Clarke |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 20% |
| Germany | 2 | 10% |
| New Zealand | 2 | 10% |
| Australia | 2 | 10% |
| Colombia | 1 | 5% |
| Unknown | 9 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 55% |
| Scientists | 4 | 20% |
| Practitioners (doctors, other healthcare professionals) | 3 | 15% |
| Science communicators (journalists, bloggers, editors) | 2 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 20% |
| Student > Ph. D. Student | 6 | 12% |
| Student > Bachelor | 5 | 10% |
| Student > Master | 4 | 8% |
| Student > Doctoral Student | 3 | 6% |
| Other | 11 | 22% |
| Unknown | 10 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 18% |
| Nursing and Health Professions | 4 | 8% |
| Economics, Econometrics and Finance | 4 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Business, Management and Accounting | 2 | 4% |
| Other | 11 | 22% |
| Unknown | 15 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2022.
All research outputs
#2,137,382
of 23,340,595 outputs
Outputs from PharmacoEconomics
#162
of 1,877 outputs
Outputs of similar age
#46,491
of 347,587 outputs
Outputs of similar age from PharmacoEconomics
#4
of 19 outputs
Altmetric has tracked 23,340,595 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,877 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 347,587 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.